Abstract-Obstructive sleep apnea (OSA) is an independent cause of resistant hypertension (RH) but its association with refractory hypertension (RfH) 
I n 2008, the American Heart Association Scientific Statement on resistant hypertension (RH) defined it as those forms of hypertension with no identifiable cause in which blood pressure (BP) levels remain uncontrolled despite the use of at least 3 antihypertensive drugs (including a diuretic, if tolerated) at full doses, with good compliance with the treatment (uncontrolled RH). This definition also covered those forms of hypertension that could be controlled by the administration of ≥4 antihypertensive drugs (controlled RH). 1 The prevalence of RH in treated hypertensive patients is estimated as being 10% to 20%. 2 RH patients present a 50% higher probability of suffering a cardiovascular event or damage to target organs than effectively controlled hypertensive patients. 3 There is a growing interest in this field because some authors have recently identified a special group of hypertensive patients affected by what is known as refractory hypertension (RfH). This is defined as those forms of hypertension that remain uncontrolled despite the administration of at least 5 antihypertensive drugs, preferably including a long-acting thiazide-like diuretic (ie, chlorthalidone) and a mineral-corticoid receptor antagonist (ie, spironolactone and eplerenone). [4] [5] [6] It is still not known whether RfH is merely the most severe end of the RH spectrum or whether it constitutes a real clinical phenotype, although some authors have favored the latter hypothesis after observing a greater dependency on the pathophysiological pathway of sympathetic activation than the renin-angiotensin-aldosterone axis. 5, 6 However, few studies have analyzed the characteristics of RfH patients, although it does seem that, in comparison with RH, RfH is more frequently found in women and black people with a particularly high cardiovascular risk. 4 Its prevalence is low, although the exact figure depends on the definition used, and most particularly whether this includes long-acting thiazide or a thiazide-like diuretic and mineralcorticoid receptor antagonist. It accounts for 2% to 10% of all RH and 1% to 2% of all treated forms of hypertension. The causes of this type of hypertension are still largely unknown. [5] [6] [7] Obstructive sleep apnea (OSA) is the most common form of sleep-disordered breathing. It is mainly characterized by recurrent episodes of partial or complete upper airway closure leading to intermittent hypoxia and sleep fragmentation. OSA occurs in 6% to 20% of men, 6% to 9% of middle-aged women, and up to 20% of the elderly in the general population. 8 Several large-scale studies have found OSA to be a risk factor for hypertension and poorer BP control, 9,10 particularly when associated with RH, in which case the prevalence of OSA reaches levels of 71% to 90%. [11] [12] [13] [14] The main pathophysiological pathway by which OSA triggers an increase in BP is the sympathetic system activation. [15] [16] [17] Continuous positive airway pressure (CPAP) is the treatment of choice in symptomatic OSA patients, and several metaanalyses have demonstrated that its correct use is associated with clinically significant drops in BP that represent ≈2 mm Hg of the mean BP. 18, 19 These reductions are even more marked in both severe OSA 18 and in patients with RH. In the latter case, they range from 4.7 to 7.9 mm Hg for systolic BP (SBP) and from 2.9 to 4.9 for diastolic BP (DBP), respectively. [20] [21] [22] [23] Given that the main pathophysiological mechanism by which OSA increases BP levels and impedes their control (activation of the sympathetic system) is the same as the mechanism believed to be the leading trigger of the appearance of RfH, our working hypothesis is that the prevalence of OSA will be higher in patients with RfH than in those with RH. Thus, the main objective of this study is to analyze the association between OSA/OSA syndrome and RfH and to compare it with a group of patients with OSA/OSA syndrome and RH.
Methods
Data supporting these findings are available from the corresponding author on reasonable request.
Study Design and Selection of Patients
A multicenter cross-sectional study was performed in patients recruited consecutively aged between 18 and 75 years diagnosed with RH (according to the American Heart Association Scientific Statement on RH 1 ) and controlled in the Hypertension Units in 24 teaching hospitals in Spain. All patients who took part in the HIPARCO randomized clinical trial (Hipertensión arterial resistente. Control con CPAP; n=194) were included in this study, as well as all those patients with confirmed RH and an apnea-hypopnea index (AHI) <15, despite not being randomized in the HIPARCO study 20 (n=35). The individuals included in this study were, therefore, consecutive patients with proven RH and a valid sleep study. Both the present study and the tests performed in all the patients were undertaken before the randomization, so any patient receiving CPAP was treated for the purposes of the present study.
All the major causes of RH (including primary aldosteronism, renal artery stenosis, and renal insufficiency) were ruled out in each Hypertension Unit. The initial exclusion criteria also included pregnancy, current use of CPAP treatment, poor adherence to antihypertensive treatment, long-term treatment with oral corticosteroids or nonsteroidal anti-inflammatory drugs, a cardiovascular event in the month before inclusion in the study, regular use of sedative drugs, such as benzodiazepines, major opiates, or antipsychotics that could significantly modify the results of sleep studies, and alcohol intake (>100 g of alcohol per day). This study was approved by the ethics committee of each participating center. All the participants provided informed signed consent to participate in the study.
Procedures

Initial Visit
At the initial visit, all the patients completed a standardized protocol that included general and anthropometric data, history of cardiovascular diseases, current medication, and clinical history related to OSA. Excessive daytime somnolence was assessed using the Epworth Sleepiness Scale (ESS) 24 and was defined as an ESS >10. Good adherence to the antihypertensive treatment was verified by means of the Haynes-Sackett test, 25 which assesses self-reported compliance. Patients were also asked to bring in the empty blister packs of their antihypertensive pills to check the number of tablets missed per month. Good adherence was considered to occur when the percentage of doses taken was between 80% and 120% of the prescribed dose.
Sleep Studies
Every patient underwent a validated home cardio-respiratory polygraphy, which included continuous recording of oronasal flow and pressure, heart rate, thoracic and abdominal respiratory movements, and oxygen saturation. Polygraphy data were scored manually by trained personnel. Apnea was defined as an interruption of oronasal airflow for >10 seconds. Hypopnea was defined as a 30% to 90% reduction in oronasal airflow for >10 seconds, associated with oxygen desaturation of ≥4%. The AHI was defined as the number of apneas plus hypopneas per hour of recording, and TSat90 was defined as the percentage of recording time with an oxygen saturation of <90%. Those tests in which the patients claimed to sleep <4 hours, or in which there were <5 hours of nocturnal recording, were repeated. Central sleep apnea was defined as at least 50% of respiratory events with a pattern of apnea or hypopnea without respiratory effort. OSA was defined as an AHI ≥5, severe OSA as an AHI ≥30, and OSA syndrome as an AHI ≥5+ESS >10.
24-Hour Ambulatory Blood Pressure Monitoring
All patients underwent an initial 24-hour ambulatory blood pressure monitoring (ABPM) measurement following international guidelines 26, 27 to confirm the presence of RH and RfH and their control. The summary values in each patient's ABPM report in the data analysis were used. Twenty-four-hour ABPM was performed using a Spacelabs 90207 automated noninvasive oscillometric device, programmed to register BP at 20-minute intervals throughout the 24-hour period. Data related to the average 24-hour, daytime, and nighttime SBP and DBP were recorded. Some indices of sympathetic tone were explored as resting heart rate and variability of BP (defined as the SD in the 24-hour mean BP). The sleeping and waking periods were determined by instructing the patients to record the approximate times when they fell asleep and woke up. Nocturnal dipping was defined by calculating night-to-day ratios for SBP and DBP. Accordingly, patients were classified as systolic or diastolic dippers (night-to-day dipping ratio ≤0.9) or nondippers (night-to-day ratio >0.9). The 24-hour ABPM criteria used to define RH were BP that remained above the target (ie, average SBP ≥130 mm Hg, average DBP ≥80 mm Hg, or both), despite the concurrent use of at least 3 antihypertensive medication agents prescribed at optimal doses-one of these being, ideally, a diuretic (if no contraindication existed)-or remained below the target with the use of >3 antihypertensive drugs. 1 In contrast, the criterion used to define RfH was a BP that remained uncontrolled in the 24-hour ABPM (ie, average SBP ≥130 mm Hg, average DBP ≥80 mm Hg, or both) in spite of the concurrent use of ≥5 antihypertensive drugs. By basing the diagnosis of RfH on the 24-hour ABPM results, we avoided diagnosing RfH resulting from a white-coat effect (office BP >140/90 mm Hg but controlled BP in the 24-hour ABPM). Therefore, we focused our research on true RfH subjects because it is these that really have a greater cardiovascular risk. Furthermore, this approach probably enabled us to identify subjects with RfH based on 24-hour ABPM results who had not been diagnosed via office BP. The 24-hour ABPM was considered satisfactory only if it fulfilled a series of preestablished criteria, including ≥80% of successful SBP and DBP recordings during the daytime and nighttime periods, 24-hour duration, and ≥1 BP measurement per hour. 28 
Statistical Analysis
Continuous variables were expressed as mean (SD), whereas categorical variables were reported as absolute and relative frequencies. The normality of the distribution of variables was tested using the Kolmogorov-Smirnov test. The baseline values of the patients with RH and RfH were compared by means of a t test or Mann-Whitney U test, depending on the distribution of the quantitative variables. The χ 2 test was used to compare dichotomous or qualitative variables. Logistic regression analysis was used to calculate the odds ratio of having severe OSA or OSA syndrome, depending on the presence of RfH rather than RH, adjusting for variables associated with the event according to the researchers´ criteria. The appropriate 95% CIs were also calculated. A 2-sided P value of <0.05 was considered significant. Data management and statistical analyses were performed using SPSS predictive analytics software (IBM), version 21.
Results
Of the initial 266 RH patients recruited from the Hypertension Units, 229 were finally included in this study (Figure) . Eleven patients with normal ABPM values who were taking >3 antihypertensive drugs were not excluded from the analysis. Of these 229 patients, 42 (18.3%) fulfilled the criteria for being considered to have RfH. Table 1 shows the clinical characteristics and comparative ABPM data for the 2 groups. Those patients with RfH presented a greater number of previous hypertensive crises, as well as greater daytime and nighttime BP in both the systolic and diastolic readings. Similarly, RfH patients presented a greater variability in their 24-hour BP levels and a higher mean heart rate. There were no differences, however, in the 2 groups' dipping patterns, except for the case of the subgroup of patients with OSA syndrome, where the percentage of individuals with a nondipper DBP pattern was higher in the group with RfH than in the group with RH. No significant differences were observed, however, in age, sex, or body mass index (BMI). The vast majority of patients were taking diuretics (except for a small percentage who could not tolerate them). The use of thiazides/thiazides-like or mineralcorticoid receptor antagonists was present in 66.7% and 21.4% of the patients, respectively. Patient with RfH used more frequently thiazides/thiazide-like diuretics (nearly significant), mineralocorticoid receptor antagonists, renin-angiotensin system blockers, calcium channel blockers, central blocking agents, and α-blockers than patients with RH. Table 2 shows the clinical characteristics associated with OSA and the results of the sleep tests, compared from group to group. Although there was a high prevalence of OSA in both the RH and RfH groups, it was significantly higher in the RfH group for both AHI cutoff points used. The prevalence of OSA syndrome was also greater in the RfH patients than in the RH group. No differences were found between the groups in the oximetric variables or clinical symptoms of OSA, including the ESS mean value. More precisely, all the patients with RfH presented an AHI ≥5 and 64% presented an AHI ≥30, whereas 52% of the patients fulfilled the criteria for OSA syndrome. Table 3 shows the results of the multivariate logistic regression analysis. After adjustments for age, sex, and BMI, those patients with severe OSA and OSA syndrome presented a 2.2 and 1.9× greater probability, respectively, of presenting RfH rather than RH.
Discussion
The main contribution of the present study is that to the best of our knowledge it is the first to analyze the relationship between OSA and 2 forms of hypertension, RH and RfH, diagnosed on the basis of 24-hour ABPM results.
Although the criterion used to define RfH was based only on a lack of BP control despite the concurrent use of ≥5 antihypertensive drugs, obviating the additional condition of treatment with a long-acting thiazide diuretic and mineral-corticoid receptor antagonist, as recommended more recently, 4 basing the diagnostic procedure on the 24-hour ABPM results allowed us to include only true RfH subjects who are really at greater cardiovascular risk. We, thus, avoided the drawbacks of a diagnosis based on office BP, such as the inclusion or subjects with white-coat effects or the exclusion of patients considered to be controlled on the basis of office BP but who prove uncontrolled on the basis of 24-hour ABPM results.
To the best of our knowledge, this is also the first study that analyzes the prevalence and characteristics of OSA and OSA syndrome in patients with RfH. We have shown that although the prevalence and severity of OSA and OSA syndrome are high in both RH (as shown in some previous articles [11] [12] [13] [14] ) and RfH patients, they are significantly higher in the latter group, despite the absence of any striking differences in the clinical characteristics, or any differences in age, sex, or BMI. Furthermore, over half of the patients with RfH presented some clinical criteria for OSA syndrome, whereas >64% were considered to have severe OSA.
There has recently been a growing interest in the identification of different clinical phenotypes of hypertensive patients who could benefit from a more personalized management of their disease. 5 Along these lines, some authors consider that there is a special phenotype within the group of patients with RH, known as RfH, with its own characteristics and pathophysiological origins (greater activation of the sympathetic system than of the renin-angiotensin-aldosterone axis, which is more closely linked with RH), although to date this hypothesis has not been fully investigated. [5] [6] [7] The relationship of RfH with the activation of the sympathetic system (the main mechanism by which OSA increases BP levels or hinders their control) gives rise to speculate about the possibility of OSA having a closer relationship with RfH than with RH.
The present study offers a series of interesting results in this respect. First, those patients with RfH presented a greater variability in 24-hour BP levels and a higher heart rate than RH patients, supporting the hypothesis that RfH triggers greater sympathetic activation than RH. 29 Second, although the number of sleep-disordered breathing is high in both RH and RfH patients, they are higher in the latter at all the cutoff points in the AHI used. In this respect, all the RfH patients presented an AHI ≥5, and 60% of them had severe OSA. It is particularly noteworthy that more than half the patients with RfH fulfilled the criteria for OSA syndrome (AHI ≥5+ESS >10). In fact, according to our results, those patients with RfH presented a 2× greater probability of presenting severe OSA (AHI ≥30) or OSA syndrome than patients with RH after adjustment for age, sex, and BMI.
The data from the studies enabled us to confirm 3 findings. First, CPAP treatment achieves statistically and clinically significant decreases in BP measurements in hypertensive patients when there is the concurrence of OSA, especially in its resistant phenotype with sleepiness as a symptom of the syndrome. [20] [21] [22] [23] Second, both OSA patients and, more particularly, RfH patients present a high cardiovascular risk 4, 5, 7, 30, 31 ; and, finally, RfH and OSA seem to share a common pathophysiological mechanism (activation of the sympathetic system) 16, 17, 29 that might explain the lack of control of these patients´ BP. In the light of these findings, the results of our study support the assertion that every RfH patient should be sent on a preferential basis to a sleep unit for a diagnosis and, where appropriate, subsequent treatment.
Another point worth noting is that there is evidence that fluid overload in RH may predispose to OSA through rostral fluid shifts. 32, 33 Supporting this hypothesis, prior studies performed to assess the effect of spironolactone in patients with RH and OSA showed that when RH subjects with OSA were treated with spironolactone, the severity of the syndrome was significantly reduced, suggesting an important component of volume overload in these subjects. 34, 35 In contrast, we think that this effect should be less marked in RfH patients because their hypertension seems to be caused more by sympathetic activation than by fluid overload. 29 However, although some antihypertensive drugs do target this pathophysiological mechanism, the evidence is that treatment of RfH patients based primarily on a pharmacological approach is inadequate. The lack of treatment of OSA, a sympathetic trigger highly prevalent in these patients, could well contribute significantly to these patients' lack of control. Therefore, this aspect endorses the assessment of OSA in these patients, as well as its treatment, where appropriate.
Another important feature is the increased prevalence of nondipping (regardless of daytime BP levels) which have been associated with increased cardiovascular risk. 36 It is well known that uncontrolled hypertension and untreated OSA are associated with nondipping BP patterns. 20 The results of our study confirm the high percentage of nocturnal nondipping patterns (particularly in SBP) found in both groups of hypertensive patients, with no significant differences between them. In RfH patients specifically, the nocturnal nondipping rates for SBP and the DBP (89.7% and 62.5%, respectively) were higher than those reported by other published studies. 7 This might be explained by the higher prevalence of previous cardiovascular disease and the obesity presented by the subjects of the present study. These clinical variables have been related to a nocturnal nondipping BP pattern. 37, 38 It should be stressed, however, that the percentage of diastolic nondippers in the group of patients with OSA syndrome was significantly higher in patients with RfH than in those with RH, although this finding does not have the same prognostic value as systolic nondipping. Finally, those patients with RfH presented more probability of having systolic nocturnal hypertension (defined as nocturnal SBP levels ≥120 mm Hg) than those patients with RH. Nocturnal hypertension has been also found to be the BP measure with the best predictive value for cardiovascular risk. [39] [40] [41] The greatest strengths of our study include its status as the first study in the literature to analyze and confirm the close relationship between RfH and OSA and the incorporation of a 24-hour BPM study for all the patients to confirm the diagnosis of RH and RfH and exclude any cases of white-coat hypertension (a relatively common occurrence, according to some authors). 7 Therefore, only patients with true RH and RfH were included in our study.
However, there are also some limitations that deserve comment. First, the prevalence of RfH was 18.3% in the RH patients, which is higher than the figure of 3% previously reported in the literature. 4, 42 This is probably because of the omission of the administration of either long-acting thiazidelike diuretics or mineral-corticoid receptor antagonists as a precondition of the diagnosis of RfH, although some other authors also made the same omission in previous studies. 7, 42, 43 Second, the high prevalence of OSA in both groups RH and RfH, might be influenced by the high BMI that is exhibited by both groups of patients, 34.7 kg/m 2 in RfH subjects and 33.9 kg/m 2 in subjects with RH. This high BMI of the recruited patients is much higher than in other published studies from our country. 7 This difference in the obesity profile might be explained by the setting in which the patients for our study were recruited: hospital hypertension units, where the most complex cases are admitted.
Third, we did not have access to the plasmatic or urinary levels of various molecules related to the sympathetic system or the renin-angiotensin-aldosterone axis, which would have confirmed their activation, although indirect variables, such as cardiac frequency and blood pressure variability were assessed to evaluate the activation of the sympathetic system. 29 Finally, OSA was diagnosed by means of a cardio-respiratory polygraphy, instead of a full polysomnography, and this may have led to an underestimation of OSA severity.
In conclusion, our results show that RfH patients present with an extraordinarily high prevalence of both OSA and OSA syndrome, at levels even higher than those found in patients with RH. This is despite the fact that OSA symptoms are similar in both groups of hypertensive patients. Furthermore, the presence of OSA syndrome could increase still further the cardiovascular risk of patients with RfH by increasing the percentage of patients with a nocturnal nondipper pattern, especially with respect to the diastolic readings.
Perspectives for the Future
This study's findings, therefore, highlight the need to actively search and identify patients with RfH and preferentially refer them for investigation of OSA because their already high level of cardiovascular risk could be further increased by the presence of an OSA syndrome. Furthermore, in severe OSA syndrome patients, CPAP treatment is effective, and in those who also have uncontrolled BP, CPAP may dramatically improve BP control. Finally, because RfH is a phenotype of hypertensive patients that has only recently been described and there is still little information about it, there is an urgent need to carry out studies to evaluate the effect of CPAP treatment on these patients, in the light of their high cardiovascular risk and their limited therapeutic options.
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